To elucidate the molecular mechanism of B7-H4 activation in the tumor microenvironment, in the future, we need to measure cytokines such as IFN-γ, examine oncogenes/oncoproteins in pathways such as the Akt/mTOR pathway and perform functional studies with anti-B7-H4 antibody in cell lines or animal models. The gene discussed is VTCN1; the disease is neoplasm.